Wednesday October 10th

7:30 AM  Registration Opens
8:30 AM  Welcome, Announcements and Keynote Speaker Introduction
          Karl Salzwedel, NIAID
8:40 AM  Keynote I: Anthony Fauci, NIAID

Martin Delaney Collaboratory Research Highlights
9:00 AM  I4C: Combined Immunological Approaches to Cure HIV-1
          Dan Barouch, Beth Israel Deaconess Medical Center
9:20 AM  BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy
          Luis Montaner, Wistar Institute
9:40 AM  BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication
          Douglas Nixon, Weill Cornell Medicine
10:00 AM CARE: Collaboratory of AIDS Researchers for Eradication
          David Margolis, University of North Carolina, Chapel Hill
10:20 AM defeatHIV: Delaney Cell and Genome Engineering Initiative
          Keith Jerome, Fred Hutchinson Cancer Research Center
10:40 AM DARE: Delaney AIDS Research Enterprise to Cure HIV
          Steven Deeks, University of California, San Francisco

11:00AM  Break (Poster Viewing and Networking)

Session I: Finding the Reservoir
Chairs: Janice Clements, Johns Hopkins University and Elizabeth Connick, University of Arizona
11:25 AM  HIV-1 Modulates Host Gene Expression at the Integration Site
          Ya-Chi Ho, Yale School of Medicine
11:40 AM  Characterizing Host Pathways that Regulate Latency in a Primary Cell Model
          Edward Browne, University of North Carolina, Chapel Hill
11:55 AM  Characterization of Latent and Active HIV Reservoirs in Blood and Tissues
          Nicolas Chomont, Université de Montréal
12:10 PM  Novel In Situ Approaches to Characterize Viral Reservoirs
          Jacob Estes, Oregon Health & Science University
12:25 PM  Developing Imaging Approaches to Define the Early Mucosal SIV Reservoir
          Thomas Hope, Northwestern University
12:40 PM  Panel Discussion
1:00 PM  Lunch (On Your Own)
2:00 PM  Poster Session
Session II: Quantifying the Reservoir
Chairs: Nancie Archin, University of North Carolina, Chapel Hill and John Mellors, University of Pittsburgh
3:15 PM  Genomic Landscapes of HIV, SIV, and SHIV: Relevance to Measuring the Latent Reservoir in Cure Studies
Robert Siliciano, Johns Hopkins University
3:30 PM  Insights into HIV Reservoir Assay Performance from the RAVEN Program
Michael Busch, Blood Systems Research Institute
3:45 PM  Determining Early HIV Decay Dynamics upon Treatment Initiation
Elizabeth Anderson, HIV Dynamics and Replication Program, NCI
4:00 PM  A Phylogenetic Approach to Estimate Integration Dates of Individual Latent HIV Sequences Within-Host
Zabrina Brumme, Simon Fraser University
4:15 PM  Using Reactivation Rates to Quantify the Viral Reservoir
Brandon Keele, AIDS and Cancer Virus Program, NCI
4:30 PM  Panel Discussion
5:00 PM  Adjourn Day 1

Thursday October 11th
8:25 AM  Announcements and Keynote Speaker Introduction
Lillian Kuo, NIAID
8:30 AM  Keynote II: CD4-mimetic Compounds: Sensitization of HIV-1 to Sub-dominant Antibody Responses
Joseph Sodroski, Dana-Farber Cancer Institute

Session III: Overcoming Latency
Chairs: Richard D’Aquila, Northwestern University and Vicente Planelles, University of Utah
9:00 AM  Dual TLR2 and TLR7 Agonists as HIV Latency-reversing Agents
Amanda Macedo, George Washington University
9:15 AM  BCL-2 Antagonism Enables CTL-Mediated Elimination of Ex Vivo CD4 Reservoirs
R. Brad Jones, Weill Cornell Medicine
9:30 AM  Systemic In Vivo Induction of the Latent HIV Reservoir via the Non-canonical NF-κB Signaling Pathway
J. Victor Garcia, University of North Carolina, Chapel Hill
9:45 AM  Latency Reversal in Nonhuman Primates
Ann Chahroudi, Emory University
10:00 AM  Combination Therapies with TLR7 Agonists
Devi SenGupta, Gilead Sciences
10:15 AM  Panel Discussion
10:45 AM  Break (Poster Viewing and Networking)
Session IV: Killing Reservoir Cells
Chairs: Sharon Riddler, University of Pittsburgh and Lydie Trautmann, Military HIV Research Program
11:05 AM Towards HIV-1 Remission with AAV-expressed eCD4-Ig
Matthew Gardner, Scripps Research Institute
11:20 AM How Many mAbs to Target the Latent Reservoir?
Guido Ferrari, Duke University
11:35 AM Novel Humanized Mouse Model to Investigate In Vivo Activation and bNAb-mediated Depletion of Patient-Derived HIV Latent Reservoirs
Harris Goldstein, Albert Einstein College of Medicine
11:50 AM Trafficking of Stem Cell-Derived CAR T-Cells to B-Cell Follicles in SHIV-Infected Nonhuman Primates
Christopher Peterson, Fred Hutchinson Cancer Research Center
12:05 PM Why HIV-specific T cells Engineered with CARs Work Better than Those Engineered with TCRs
James Riley, University of Pennsylvania
12:20 PM HIV-Resistant CAR T Cells in SHIV-infected Non-human Primates
Thor Wagner, Seattle Children's Hospital
12:35 PM Panel Discussion

1:00 PM Lunch (On Your Own)

2:00 PM Poster Session

Session V: Immunomodulation and Immunologic Control of Viremia
Chairs: Jonathan Karn, Case Western Reserve University and Jeffrey Lifson, Frederick National Laboratory
3:00 PM Understanding CD8+ T Cell Function During Antiretroviral Therapy
Afam Okoye, Oregon Health & Science University
3:15 PM Generating Functional HIV-specific CD8+ T Cells
Rachel Rutishauser, University of California, San Francisco
3:30 PM Myeloid-derived Suppressor Cells Expand During Analytic treatment Interruption and Decrease Anti-viral T cell Responses in Combinatorial HIV Curative Therapy
Sandra Dross, University of Washington
3:45 PM Combination Immunotherapy to Induce Viral Remission
James Whitney, Beth Israel Deaconess Medical Center
4:00 PM Neutralizing Antibody-Based HIV Cure Strategies
Dan Barouch, Beth Israel Deaconess Medical Center
4:15 PM Effects of Broadly Neutralizing Antibody Combinations in HIV-1 Infection
Marina Caskey, Rockefeller University
4:30 PM Panel Discussion

5:00 PM Adjourn Day 2
Friday October 12th

8:25 AM  Announcements and Keynote Speaker Introduction  
Roger Miller, NIAID

8:30 AM  Keynote III: Silencing the HIV-1 Reservoir  
Susana Valente, Scripps Research Institute

Session VI: Clinical Trials and Community Engagement  
Chairs: Adriana Andrade, NIAID and Joseph Eron, University of North Carolina, Chapel Hill  
Panelists: Richard Jeffreys, Treatment Action Group and A. Toni Young, Community Education Group

9:00 AM  Meeting Report: Framework for Initiating Pediatric Studies of HIV Cure Interventions  
Deborah Persaud, Johns Hopkins University

Boris Juelg, Ragon Institute

9:30 AM  Acceptability of Target Product Profiles for an HIV Cure Regimen According to Adults Living with HIV in the U.S.  
Karine Dubé, University of North Carolina, Chapel Hill

9:45 AM  The Last Gift: Performing HIV Cure Research at the End of Life  
Sara Gianella Weibel, University of California, San Diego

10:00 AM  Panel Discussion

10:30 AM  Break (Poster Viewing and Networking)

Session VII: Viral Rebound and Post Treatment Control  
Chairs: Rajesh Gandhi, Massachusetts General Hospital and Nelson Michael, Military HIV Research Program

10:50 AM  Lessons Learned from Brief ATI Trials in the RV254 Cohort to Inform Future ATI Designs  
Jintanat Ananworanich, Military HIV Research Program

11:05 AM  Preliminary Testing of a bNAb Susceptibility Screening Assay  
Katherine Bar, University of Pennsylvania

11:20 AM  The Majority of the Replication-competent Virus in the Latent Reservoir Originates from Viruses Replicating Near the Time of ART Initiation  
Sarah Joseph, University of North Carolina, Chapel Hill

11:35 AM  Impact of Analytical Treatment Interruption on HIV Dynamics  
Tae-Wook Chun, NIAID

11:50 AM  Understanding Post-Treatment HIV Control  
Jonathan Li, Brigham and Women's Hospital

12:05 PM  Panel Discussion

12:30 PM  Closing Remarks, Adjourn  
Karl Salzwedel, NIAID